International Clinical Trial: Safety and Efficacy of Hepatic Arterial Infusion Chemotherapy (GP Regimen) Combined with Intraoperative Arterial Infusion of Envafolimab plus Lenvatinib for Unresectable Biliary Tract Cancer: A Multicenter, Singlearm, Phase IbII Clinical Study

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132815) titled 'Safety and Efficacy of Hepatic Arterial Infusion Chemotherapy (GP Regimen) Combined with Intraoperative Arterial Infusion of Envafolimab plus Lenvatinib for Unresectable Biliary Tract Cancer: A Multicenter, Singlearm, Phase IbII Clinical Study' on Sept. 18.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: West China Hospital of Sichuan University

Condition: Unresectable biliary tract cancer

Intervention: Phase Ib Trial Group 3:Envafolimab 400?mg Q3W cohort Phase Ib Trial Group 1:Envafolimab 200?mg Q3W cohort Phase Ib Trial Group 2:Envafolimab 300?mg Q3W cohort

Recruitment Status...